Market Overview

Merrimack Plummets 30% After Pancreatic Cancer Drug Doesn't Meet Endpoints

Share:
Merrimack Plummets 30% After Pancreatic Cancer Drug Doesn't Meet Endpoints

Merrimack Pharmaceuticals Inc (NASDAQ: MACK) plunged more than 30 percent Monday after management discontinued the development of MM-141.

The drug’s Phase 2 trial for MM-141 in front-line metastatic pancreatic cancer did not meet primary or secondary endpoints.

Why It’s Important

This is the second time in 18 months that Merrimack has killed a Phase 2 candidate. Its stock never recovered from the discontinuation of MM-302, which catalyzed an 80-percent drop.

With the latest failure, Merrimack will redirect its resources to the advancement of MM-121, a candidate with orphan drug designation currently involved in two Phase 2 studies for non-small cell lung cancer (NSCLC) and metastatic breast cancer. It will also heighten its focus on MM-310 engaged in a Phase 1 study in solid tumors.

"While these results are disappointing, looking forward our focus remains on the continued development of our deep, wholly-owned pipeline, including two clinical programs, MM-121 and MM-310, with data readouts expected in 2018," Richard Peters, president and CEO of Merrimack, said in a press release.

What’s Next

The company will report results from the MM-310 trial and the MM-121 study on NSCLC in the second half of the year.

At time of publication, shares were trading around $6.02, down 33 percent.

Related Links:

Analyst: Merrimack Pharma Is Taking Steps In The Right Direction

Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives

Posted-In: cancer MM-141News Health Care Top Stories Movers Trading Ideas General Best of Benzinga

 

Related Articles (MACK)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Mid-Morning Market Update: Markets Open Lower; Carnival Cuts Profit Forecast

Investors Might Be Worried by Trade Issues With Europe, China